| ¿µ¹® | antihypertensive drug | ÇÑ±Û | °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦ |
|---|---|---|---|
| ¼³¸í | °íÇ÷¾ÐÀÇ Ä¡·á¿¡ »ç¿ëÇÏ¸ç ³ôÀº Ç÷¾ÐÀ» ³·Ãß´Â ¾à¹°À» ¸»ÇÑ´Ù. °íÇ÷¾Ð¾à¿¡´Â Ç÷°üÆòȰ±Ù¿¡ Á÷Á¢ ÀÛ¿ëÇÏ¿© À̿ϽÃŰ´Â Ç÷°üÈ®ÀåÁ¦(È÷µå¶ó¶óÁø), ±³°¨½Å°æÀÇ È°µ¿À» ¾îµð¼±°¡ Â÷´ÜÇÏ´Â ¾à¹°(·¹¼¼¸£ÇÉ, ¸ÞÆ¿µµÆÄ, ÇÁ·ÎÇÁ¶ó³ë·Ñ), ÀÌ´¢Á¦(ÇÁ·Î¼¼¹Ìµå, ¿¡Å¸Å©¸°»ê)ÀÌ »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | antimalarial drug | ÇÑ±Û | ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦ |
|---|---|---|---|
| ¼³¸í | ¸»¶ó¸®¾Æ Ä¡·á¿¡ ¾²´Â ¾à. Ű´Ï³×, Ŭ·Î·ÎÄý, ÇÁ¸®¸¶Äý µûÀ§°¡ ÀÖ´Ù. ¸»¶ó¸®¾Æ ¿øÃæÀÇ ¹ßÀ°Áֱ⿡ ´ëÀÀÇØ¼ ¾à¹°ÀÌ ÀÖÀ¸³ª ´ëºÎºÐÀº º´¿ë¿ä¹ý¿¡ µû¶ó¼ ¸»¶ó¸®¾Æ Ä¡·á¸¦ ÇÑ´Ù. ¸ð±â¿¡ ÀÇÇÑ Æ÷ÀÚü°¨¿°¿¡ ´ëÇÑ Çׯ÷ÀÚü ¾àÀº µ¶¼º µîÀÇ ¹®Á¦°¡ ÀÖ¾î¼ ¾ÆÁ÷ ¾ø´Ù. ÀûÇ÷±¸³»¿¡¼ÀÇ È¯»óü, ¹ø½Äü¿¡¸¸ ÀÛ¿ëÇÏ´Â °Í(Ç×¹ø½Äü ¾àÀº Ŭ·Î·ÎÄý, ÇǸ®¸ÞŸ¹Î, Ŭ·Î·Î±¸¾Æ³ªÀ̵å, Ű´Ï³×)Àº ÀûÇ÷±¸ ¿ÜÀÇ ¹ßÀ°Àº ¾ïÁ¦ÇÏÁö ¾ÊÀ¸¹Ç·Î °¨¿°À» ¿ÏÀüÈ÷ ÀúÁöµÇÁö ¾Ê´Â´Ù. ÀûÇ÷±¸³»¿ÜÀÇ ¿øÃæ¿¡ ÀÛ¿ëÇØ ¿ÏÀüÈ÷ °¨¿°À» ¾ïÁ¦ÇÏ´Â °Í(ÆÄ¸¶Å², ÆæÅ¸Å², ÇÁ¸®¸¶Å²), Ç÷ÁßÀÇ »ý½Äü¸¦ Á×ÀÌ´Â °Í(´ëºÎºÐÀÇ Ç׸»¶ó¸®¾ÆÁ¦)Àº ¸ð±â¿¡ ÀÇÇÑ Å¸ÀÎÀ¸·ÎÀÇ Àü¿°¿øÀº ²÷±â´Âµ¥ ȯÀÚÀÚ½ÅÀÇ Áõ»óÀº º¯ÈÇÏÁö ¾Ê´Â´Ù. |
||
| ¿µ¹® | drug | ÇÑ±Û | ¾à, ¾à¹°, ¾àÁ¦ |
|---|---|---|---|
| ¼³¸í | 1. º´, ±âŸ º´Àû »óÅÂÀÇ Áø´Ü, Ä¡·á, ¿¹¹æÀ̳ª °íÅëÀÇ °æ°¨, ¶Ç´Â »ý¸®Àû, º´¸®Àû »óŸ¦ È£Àü½ÃŰ´Â °ÍÀ» ¸ñÀûÀ¸·Î »ç¶÷ ¶Ç´Â µ¿¹°¿¡ Åõ¿©µÇ´Â ÈÇÕ¹°. ¾à¸®Çп¡¼´Â Ä¡·á¾à¸¸ÀÌ ¾Æ´Ï¶ó, »ýü¿¡ ÁÖ¾îÁ³À» ¶§ ¾î¶°ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»´Â ÈÇй°Áú ¸ðµÎ¸¦ ¾à¹°À̶ó°í ÇÑ´Ù. ÀÛ¿ëÀÌ °ÇÏ°í ¾ÈÀü¼ºÀÌ ³·Àº ¼ø¼·Î µ¶¾à-±Ø¾à-º¸Åë¾àÀ¸·Î ±¸ºÐÇϰí ÀÖ´Ù. ¾à¹°Ä¡·á¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀڷμ, »ýüÂÊ ÀÎÀڷδ °³Ã¼Â÷, ¿¬·É, üÁß µîÀÌ ÀÖ°í, ¾à¹°ÂÊ ÀÎÀڷμ´Â Åõ¿©¹æ¹ý, Åõ¿©·®, º´¿ëµÇ°í ÀÖ´Â ´Ù¸¥ ¾à¹° µîÀÌ ÀÖ´Ù. 2. ¾àÀÇ Àç·á°¡ µÇ´Â ¹°Áú. 3. ¿©·¯ °¡Áö ¾àÀ縦 ¼¯¾î Á¶Á¦ÇÑ ¾à. |
||
| ¿µ¹® | drug resistance | ÇÑ±Û | ¾à¹°³»¼º |
|---|---|---|---|
| ¼³¸í | 1. ÈÇпä¹ýÁ¦³ª Ç×»ý¹°ÁúÀÇ ¾î¶² ÀÏÁ¤ ³óµµ·Î ¼¼±ÕÀ» Á×À̰ųª Áõ½ÄÀúÇØ¸¦ ¹Þ´Â °ÍÀ» ÀÌ ÈÇпä¹ýÁ¦³ª Ç×»ý¹°Áú¿¡ °¨¼ö¼ºÀÌ ÀÖ´Ù°í Çϴµ¥, ÀÌ °¨¼ö¼ºÀÌ ¾ø°Ô µÈ »ýŸ¦ ÀúÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. µû¶ó¼ º¯À̹̻ý¹°ÀÇ ¾àÁ¦¿¡ ´ëÇÑ ÀÚÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. 2. ÀǾàǰÀ» °è¼Ó º¹¿ëÇϸé Á¡Â÷ Áõ·®ÇÏÁö ¾ÊÀ¸¸é È¿·ÂÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¼ºÁú. ÀÌ·¯ÇÑ ¶§¸¦ ¾àÁ¦³»¼ºÀÌ »ý°å´Ù°í ÇÑ´Ù. ¸ðµç ¹Ì»ý¹°Àº °¨¼ö¼ºÀ» °¡Áö´Â ¾à¹°¿¡ ÀÇÇÏ¿© »ç¸êµÇÁö¸¸, ¼Ò¼öÀÇ °ÍÀº »ì¾Æ³²¾Æ ±×°ÍÀÌ ÁøÈµÊÀ¸·Î½á »ç¸êÇÏÁö ¾Ê´Â ¼ö°¡ ÀÖ´Ù. ¶Ç, ÃÖÃÊ¿¡´Â °¨¼ö¼ºÀ» °¡Áö°í ÀÖ´ø ±ÕÀÌ Â÷Â÷ ³»¼º±ÕÀ¸·Î µÇ±âµµ ÇÑ´Ù. ¸¹Àº º´¿ø±ÕÀº °¨¼ö¼ºÀÌ ÀÖ´Â ÀǾàǰ¿¡ ´ëÇÏ¿© ³»¼ºÀÌ »ý±ä´Ù. °¡Àå °íµµÀÇ ³»¼º±ÕÀÌ »ý±â±â ½¬¿î °ÍÀº ½ºÆ®·¾Å丶À̽ÅÀε¥ °áÇÙ±Õ°ú ±×¶÷À½¼º±Õ¿¡ ´ëÇÏ¿© ½±°Ô ³»¼ºÀÌ »ý±ä´Ù. Æä´Ï½Ç¸°À̳ª Åׯ®¶ó½ÃŬ¸°(¾ÆÅ©·Î¸¶À̽Å) µîÀÇ Ç×»ý¹°Áúµµ ³»¼ºÀÌ »ý±â±â ½¬¿ì¹Ç·Î, »ç¿ëÇÒ ¶§´Â ÀûÀÀÀ» Àß È®ÀÎÇÏ¿© Çʿ䷮À» Á¤ÇÏ°í ¿¬¿ëÀ» ÇÇÇÑ´Ù. °°Àº È¿°ú°¡ ÀÖ´Â ´Ù¸¥ Á¾·ùÀÇ ¾àÁ¦¸¦ ¼Ò·®¾¿ 2, 3Á¾ º´¿ëÇÏ¸é ³»¼ºÀÇ ¹ß»ýÀÌ Å©°Ô ¾ïÁ¦µÈ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. °áÇÙ¾àÀ¸·Î¼ ½ºÆ®·¾Å丶À̽Űú ÆÄ½º, ¶Ç´Â À̼ҴϾÆÁöµå¸¦ º´¿ëÇÏ´Â °Í µîÀÌ ±× ¿¹ÀÌ´Ù. |
||
| ¿µ¹® | drug dependence | ÇÑ±Û | ¾à¹°ÀÇÁ¸(¼º) |
|---|---|---|---|
| ¼³¸í | ¾î¶² Á¾·ùÀÇ ¾à¹°À» ¹Ýº¹Çؼ »ç¿ëÇÏ´Â µ¿¾È ±× ¾àÀÇ »ç¿ëÀ» ÁßÁöÇÒ ¼ö ¾ø°Ô µÇ´Â »óÅÂ. ÀÇÁ¸ÀÇ Á¤µµ°¡ ½ÉÇØÁö¸é ¾à ¾øÀÌ´Â »ýȰÇÒ ¼ö ¾ø´Â »óÅ¿¡ ºüÁö°í, ±× °á°ú ¹ýÀ» ¾î±â¸é¼±îÁö ¾àÀ» ±¸ÀÔÇÏ°Ô µÈ´Ù. ÀÌÀü¿¡´Â ¾à¹°¸¸¼ºÁßµ¶, ¾à¹°³²¿ë, ¾à¹°½À°ü¼ºÀ̶ó´Â °³³äÀ¸·Î ³ª´©¾îÁ® ÀÖ¾úÁö¸¸, WHO¿¡¼´Â À̰͵éÀ» ¸ðµÎ Æ÷ÇÔ½ÃÄѼ ¾à¹°ÀÇÁ¸À̶ó ÇÏ¿´´Ù. »óÅ¿¡ ÀÇÇÑ ºÐ·ù¶ó ¾à¹°ÀÛ¿ë¿¡ ÀÇÇÑ ºÐ·ù°¡ ÀÖ´Ù. »óÅ¿¡ ÀÇÇÑ °ÍÀº 1.Á¤½ÅÀû ÀÇÁ¸: ¾à¹°ÀÇ »ç¿ëÀ» ÁßÁöÇÏ¸é ºÒ¾È°¨-¿ì¿ï°¨-ÃÊÁ¶°¨ µîÀÇ ½É¸®ÀûÀÎ Áõ»óÀÌ ³ªÅ¸³ª ´Ù½Ã ¾à¹°À» ã°Ô µÇ´Â °æ¿ì. ¾àÀ» ²÷¾úÀ» °æ¿ì¿¡ ³ªÅ¸³ª´Â ½ÅüÁõ»óÀÎ ±Ý´ÜÁõ»óÀº ³ªÅ¸³ªÁö ¾ÊÀ¸¸ç, ¾à¹°ÀÇ Áö¼ÓÀû º¹¿ë¿¡ ÀÇÇØ¼ Á¡Â÷ ¾à¹°¿¡ ´ëÇÑ ½ÅüÀÇ ¹ÝÀÀÀÌ ÁÙ¾îµå´Â Çö»óÀÎ ¾à¹°ÀÇ ³»¼ºµµ ³ªÅ¸³ªÁö ¾Ê´Â´Ù. 2.½ÅüÀû ÀÇÁ¸: ¾à¹° »ç¿ëÀ» ÁßÁöÇÏ¸é ½ÅüÀûÀÎ Àå¾Ö, Áï ±Ý´ÜÁõ»óÀ» ÀÏÀ¸Å°°í ±× °íÅëÀ» ´Þ·¡±â À§ÇØ ¾à¹°À» ã°Ô µÇ´Â °æ¿ìÀÌ´Ù. ´ëºÎºÐ ³»¼ºÀÌ ³ªÅ¸³ª´Âµ¥ °³º°ÀûÀ¸·Î ³ªÅ¸³ª´Â °æ¿ìµµ ÀÖÁö¸¸ ÁÖ·Î º´ÇàÇØ¼ ³ªÅ¸³´Ù. |
||
| DA | dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis... |
|---|---|
| CP | candle power; capillary pressure; cardiac pacing; cardiac performance; cardiopulmonary; caudate puta... |
| CPT | carnitine palmityl transferase; carotid pulse tracing; chest physiotherapy; child protection team; c... |
| PD | Doctor of Pharmacy; Dublin Pharmacopoeia; interpupillary distance; Paget disease; pancreatic duct; p... |
| RPS | renal pressor substance; revolutions per second |
| CPT | Cold Pressor Test |
|---|---|
| CP | cold pressor |
| ADAP | AIDS Drug Assistance Program |
| ADE | Adverse Drug Event |
| ADR | Adverse Drug Reaction |
| drug-drug interaction | The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity. (09 Oct 1997) |
|---|---|
| cold pressor test | A cardiocirculatory challenge conventionally performed by immersing one hand in ice cold water for two or more minutes (as tolerated) to acutely raise the blood pressure, thus imposing resistance to ejection of blood from the left ventricle into the systemic arterial system and consequently acutely increased afterload (afterload = increased left ventricular wall stress). Synonym: Hines-Brown test. (05 Mar 2000) |
| pressor | <physiology> Causing, or giving rise to, pressure or to an increase of pressure; as, pressor nerve fibres, stimulation of which excites the vasomotor center, thus causing a stronger contraction of the arteries and consequently an increase of the arterial blood pressure. Compare: depressor. (05 Mar 1998) |
| pressor amine | One of several products of intestinal putrefaction believed to cause functional hypertension when absorbed, any alkaline substance that raises blood pressure. Synonym: pressor amine, pressor substance. (05 Mar 2000) |
| pressor base | One of several products of intestinal putrefaction believed to cause functional hypertension when absorbed, any alkaline substance that raises blood pressure. Synonym: pressor amine, pressor substance. (05 Mar 2000) |
| pressor fibres | Sensory nerve fibre's whose stimulation causes vasoconstriction and rise of blood pressure. (05 Mar 2000) |
| pressor nerve | An afferent nerve, stimulation of which excites a reflex vasoconstriction, thereby raising the blood pressure. (05 Mar 2000) |
| pressor substance | One of several products of intestinal putrefaction believed to cause functional hypertension when absorbed, any alkaline substance that raises blood pressure. Synonym: pressor amine, pressor substance. (05 Mar 2000) |
| abnormalities, drug-induced | Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. (12 Dec 1998) |
| activity, drug | A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa). (12 Dec 1998) |
| addictive drug | Any drug that creates a certain degree of euphoria and has a strong potential for addiction. (05 Mar 2000) |
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
| akathisia, drug-induced | Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation). (12 Dec 1998) |
| antineoplastic drug | A drug that stops or slows the maturation and spread of tumour cells (benign or malignant). (09 Oct 1997) |
| maintenance drug therapy | In chemotherapy, systematic dosage at a level that maintains protection against exacerbation. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|